Rapamycin (sirolimus) was discovered in a soil sample from Easter Island (Rapa Nui — hence the name) in the 1970s, initially developed as an antifungal agent, and subsequently found to be a potent immunosuppressant used in organ transplantation. It inhibits a protein complex called mTORC1 (mechanistic Target Of Rapamycin Complex 1) — which, as subsequent decades of research established, is one of the most central regulators of cellular aging, metabolism, and lifespan across virtually every species studied. In 2009, Harrison et al. published a result that changed the field: rapamycin, started at an age equivalent to 60 years in humans, extended median lifespan in genetically heterogeneous mice by 9% in males and 14% in females — the first demonstration that a pharmacological intervention could extend lifespan when started in already-old mammals.
That result, replicated across three independent research sites through the NIA's Interventions Testing Program (ITP), triggered a wave of interest in rapamycin as a potential human longevity drug. A subset of longevity-focused physicians began prescribing it off-label to healthy adults. The Dog Aging Project is testing it in companion dogs. The PEARL trial (2023–2026) is the first human RCT of rapamycin in healthy adults specifically designed to measure aging biomarkers. The excitement is scientifically grounded. The certainty about human benefit is not yet established. This guide separates those two things.
| Compound | ITP Result (median lifespan extension) | Mechanism | Human Translation |
|---|---|---|---|
| Rapamycin | Males +9–26%, Females +14–21% (dose and start-age dependent) | mTORC1 inhibition → autophagy, reduced senescence | Off-label human use growing; PEARL trial ongoing; best-supported drug candidate |
| Acarbose | Males +22%, Females +5% (sex-specific) | Alpha-glucosidase inhibitor → blunts postprandial glucose spikes | FDA-approved T2D drug; very cheap; minimal side effects; some longevity physicians add to rapamycin protocol |
| 17α-Estradiol | Males +19%, Females: no effect (sex-specific) | Non-feminizing estrogen; reduces mTOR activity; mechanism unclear | Not FDA-approved for human use at low doses; compounding pharmacies; male-only benefit is intriguing |
| Canagliflozin (Jardiance-class) | Males +14%, Females: no significant extension | SGLT2 inhibitor → caloric restriction mimicry, AMPK activation | FDA-approved for T2D + HF; cardiac and renal benefits established; off-label in healthy adults: growing interest |
| Metformin | Pending (TAME trial in humans started first) | AMPK activation, mTOR suppression, mitochondrial complex I inhibition | FDA-approved T2D; TAME trial (N=3,000) testing in healthy aging adults; results ~2027 |
| NMN / NR (NAD+ precursors) | No ITP lifespan extension published | NAD+ restoration → sirtuin activation | Strong mechanistic rationale but no ITP lifespan data; widely used; trial evidence limited |
| Resveratrol | No ITP extension | SIRT1 activation | Extensive hype not supported by ITP; poor bioavailability; low confidence |
Immunosuppression at high doses: at transplant doses (1–6mg/day continuously), rapamycin significantly suppresses the immune system and increases infection risk, including opportunistic infections; at the intermittent low doses used by longevity physicians (typically 2–6mg once weekly or every 2 weeks), the immunosuppressive effect is substantially lower; the 2022 Mannick pilot study showed improved (not reduced) vaccine response in elderly adults at 0.5mg/day — suggesting the dose and schedule are critical; however, any immune effect is relevant for cancer surveillance and infection risk.
Metabolic effects: rapamycin can cause insulin resistance and hyperlipidemia at therapeutic doses; these effects appear dose-dependent and may be less pronounced at longevity dosing; regular metabolic monitoring (fasting glucose, HbA1c, lipid panel) is standard in any physician-supervised rapamycin protocol.
Wound healing impairment: mTOR inhibition reduces protein synthesis; wound healing is slowed; longevity physicians typically recommend pausing rapamycin 2–4 weeks before any planned surgery or major injury period.
Drug interactions: rapamycin is metabolized by CYP3A4; many common medications affect this pathway; grapefruit and St. John's Wort significantly alter rapamycin blood levels; co-administration with other CYP3A4 inhibitors (many antifungals, some antibiotics, some heart medications) can raise rapamycin to dangerous levels; drug interaction review is mandatory before starting.
No approved longevity indication: rapamycin is FDA-approved for: organ transplant rejection prevention, certain kidney cancers, certain rare lung diseases; it is not approved for anti-aging or longevity; off-label prescribing is legal but the physician assumes liability; any healthy adult taking rapamycin is participating in an uncontrolled experiment with real biological risks; this is not a benign supplement — it is a drug with meaningful side effect potential.
Typical dosing protocols (vary widely — no consensus): the most commonly reported approach among longevity physicians (Attia, Huberman guests, Kaeberlein protocols) is weekly intermittent dosing rather than daily continuous dosing; this approach is based on the hypothesis that intermittent mTOR inhibition achieves the longevity benefits with less immunosuppression than continuous dosing; common starting doses: 2–5mg once weekly; some physicians use 5–10mg once weekly; some use every-other-week; blood level monitoring (rapamycin trough levels) is used by some but not all; rapamycin is taken with a small amount of fat (improves absorption — it is lipophilic).
What physicians monitor: CBC with differential (immune cell counts), comprehensive metabolic panel (glucose, kidney function), fasting lipid panel, HbA1c, biological age clock testing (optional but informative — TruAge, Levine clock, or similar methylation-based tests); monitoring frequency: monthly for first 3–6 months, then quarterly once stable.
The context question — who is actually taking this: self-reported rapamycin use in healthy adults is concentrated among: people with strong longevity focus who have followed the scientific literature closely, executives and high-net-worth individuals who work with longevity physicians (cost: physician visits + lab tests + drug = $200–500+/month), and a subset of researchers who have read the primary literature; this is not (and probably should not be) a mass consumer intervention at this stage of evidence development; it is appropriate for healthy adults who have: physician oversight, have read and understood the primary literature, accept the experimental nature, have adequate metabolic monitoring, and have no contraindications.
What the PEARL trial will tell us: whether weekly low-dose rapamycin in healthy 50–85-year-olds actually moves biological age biomarkers vs placebo; this is the first true test of the longevity hypothesis in humans with proper controls; if results are positive, rapamycin's off-label longevity use will expand significantly and may eventually drive an FDA submission for an aging indication.
As an Amazon Associate, LongevityLab earns from qualifying purchases made through links on this page. This does not affect the price you pay.